The Center for Autism and Related Disorders, a provider of early intensive behavioral intervention for individuals with autism spectrum disorder, will now offer Lineagen's FirstStepDx test as a service to CARD patients and their families.
NEW YORK (GenomeWeb News) – Agilent Technologies this week said that its board of directors has declared a quarterly dividend of $.10 per share payable on July 25 to all shareholders of record as of July 3.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Molecular diagnostics firm Lineagen and Fast Forward have forged a partnership to fund the development of a blood-based assay for multiple sclerosis.
Lineagen's new chromosomal microarray testing and genetic-counseling service, dubbed FirstStepDx, aims to appeal to pediatricians who are charged with treating children with possible autism spectrum disorder or developmental delay.
The newly raised $5 million brings the total Series A round amount to $10.8 million, which the company will use to develop its autism program and support its planned commercial service launch in September.